Literature DB >> 19667307

APOE genotype, lipids, and coronary heart disease risk: a prospective population study.

Heather Ward1, Panagiota N Mitrou, Richard Bowman, Robert Luben, Nicholas J Wareham, Kay-Tee Khaw, Sheila Bingham.   

Abstract

BACKGROUND: The risk of coronary heart disease (CHD) may be related to genetic mutations in the production of apolipoprotein E via alterations to the metabolism of CHD-related blood lipids such as low-density lipoprotein cholesterol and triglycerides.
METHODS: The relationship between APOE genotype (*E3/*E3, *E3/*E4, *E2/*E3, *E4/*E4, *E2/*E4, and *E2/*E2) and fatal and nonfatal CHD was examined among 10 035 men and 12 134 women, aged 440 to 79 years, from the Norfolk, England, arm of the European Prospective Into Nutrition and Cancer Study (1993-2007). During an average of 11 years of follow-up, 2712 CHD events were documented.
RESULTS: The hazard ratio for CHD was 0.88 (95% confidence interval, 0.77-0.99) for *E2 carriers (*E2/*E2 and *E2/*E3) and 1.09 (1.00-1.19) for *E4 carriers (*E3/*E4 and *E4/*E4) compared with homozygous *E3/*E3 individuals after age and sex adjustment. Similar values were obtained when systolic blood pressure, body mass index, diabetes mellitus, alcohol intake, physical activity, and smoking were added to the model. After additional adjustment for baseline levels of the ratio of low- to high-density lipoprotein cholesterol, the hazard ratios (and 95% confidence intervals) for *E2 and *E4 carriers were 0.97 (0.85-1.10) and 1.06 (0.97-1.15), respectively, when compared with *E3 homozygotes. No interactions by sex, smoking status, or age groups were observed.
CONCLUSION: In the largest prospective cohort study to date, CHD risk was not associated with APOE genotype after controlling for a variety of cardiovascular risk factors, particularly the ratio of low- to high-density lipoprotein cholesterol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667307     DOI: 10.1001/archinternmed.2009.234

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  45 in total

1.  Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Authors:  Marguerite R Irvin; Edmond K Kabagambe; Hemant K Tiwari; Laurence D Parnell; Robert J Straka; Michael Tsai; Jose M Ordovas; Donna K Arnett
Journal:  Circ Cardiovasc Genet       Date:  2010-08-21

2.  ApoE isoforms, treatment of diabetes and the risk of coronary heart disease.

Authors:  Hideki Ehara; Ritsuko Yamamoto-Honda; Hiroji Kitazato; Yoshihiko Takahashi; Shoji Kawazu; Yasuo Akanuma; Mitsuhiko Noda
Journal:  World J Diabetes       Date:  2012-03-15

3.  Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China.

Authors:  Zhixiong Zhong; Heming Wu; Bin Li; Cunren Li; Zhidong Liu; Min Yang; Qifeng Zhang; Wei Zhong; Pingsen Zhao
Journal:  J Clin Lab Anal       Date:  2018-02-09       Impact factor: 2.352

Review 4.  Candidate gene-environment interaction research: reflections and recommendations.

Authors:  Danielle M Dick; Arpana Agrawal; Matthew C Keller; Amy Adkins; Fazil Aliev; Scott Monroe; John K Hewitt; Kenneth S Kendler; Kenneth J Sher
Journal:  Perspect Psychol Sci       Date:  2015-01

5.  Human apolipoprotein E genotypes differentially modify house dust mite-induced airway disease in mice.

Authors:  Xianglan Yao; Cuilian Dai; Karin Fredriksson; Jonathan Lam; Meixia Gao; Karen J Keeran; Gayle Zywicke Nugent; Xuan Qu; Zu-Xi Yu; Neal Jeffries; JingPing Lin; Maryann Kaler; Robert Shamburek; Rene Costello; Gyorgy Csako; Morten Dahl; Børge G Nordestgaard; Alan T Remaley; Stewart J Levine
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-11-04       Impact factor: 5.464

6.  Familial genetic risk factors in premature cardiovascular disease: a family study.

Authors:  Oguzhan Yucel; Oguz Karahan; Ali Zorlu; Sinasi Manduz
Journal:  Mol Biol Rep       Date:  2011-12-28       Impact factor: 2.316

7.  Does Apolipoprotein E genotype affect cardiovascular risk in subjects with acromegaly?

Authors:  Vildan Bozok Cetintas; Ayhan Zengi; Asli Tetik; Muammer Karadeniz; Faruk Ergonen; Ali Sahin Kucukaslan; Sadik Tamsel; Buket Kosova; Serap Baydur Sahin; Fusun Saygılı; Zuhal Eroglu
Journal:  Endocrine       Date:  2011-12-27       Impact factor: 3.633

Review 8.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

9.  APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population.

Authors:  Rafael O Alvim; Silvia R S Freitas; Noely E Ferreira; Paulo C J L Santos; Roberto S Cunha; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  Lipids Health Dis       Date:  2010-11-08       Impact factor: 3.876

10.  Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly.

Authors:  Mary N Haan; Elizabeth R Mayeda
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.